Chargement en cours...
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma
IMPORTANCE: Treatment with atezolizumab plus bevacizumab may prolong overall survival among patients with unresectable hepatocellular carcinoma. However, to our knowledge, the cost-effectiveness of using this high-priced therapy for this indication is currently unknown. OBJECTIVE: To evaluate the co...
Enregistré dans:
| Publié dans: | JAMA Netw Open |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Medical Association
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7905498/ https://ncbi.nlm.nih.gov/pubmed/33625508 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2021.0037 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|